New data provide key mechanistic insights into how TG4050 induces and sustains potent, CD8+ T cell responses in operable HNSCC[*] patients Comprehensive immunogenicity data demonstrate TG4050’s ability to induce neoantigen-specific cytotoxic CD8+ T cell responses capable of targeting and eliminating tumor cells, supporting its potential to reduce risk of relapse Conference call scheduled on November 14 at 4 p.m. CET (in English). See details below. Strasbourg, France & Tokyo, Japan, November 4, 2025, 5:45 ...

Novanta (NasdaqGS:NOVT) Q3 2025 Earnings Call November 04, 2025 08:30 AM ET Speaker1Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to Novanta's third quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. To ask a question, you may press star then one on your touch-tone phone. To withdraw your question, please press ...

监管审批里程碑 - Sequel II CNDx系统获得中国国家药品监督管理局（NMPA）的三类医疗器械注册批准，这是通过与贝瑞基因的长期合作实现的[1] - 此次批准标志着全球首个临床级长读长测序仪获得监管许可，预示着中国精准医学和高精度基因组检测进入新纪元[2] - 贝瑞基因由此成为全球首家获授权在临床环境中部署长读长测序平台的公司[6] 技术与产品优势 - 该系统利用单分子实时测序技术，能够提供超过20kb的长读长和高准确性，是唯一能同时实现这两项优势的技术[5] - 与贝瑞基因新获批的地中海贫血临床检测试剂及软件系统结合，为中国医院和诊断实验室提供了首个端到端的长读长测序工作流程[4] - 该技术能在单次测试中全面捕获基因组信息，包括单核苷酸变异、插入缺失、拷贝数变异、结构变异和重复扩增，尤其适用于短读长测序难以检测的复杂变异类型[2][3][5] 市场与应用前景 - 该工作流程针对携带者筛查、产前诊断、新生儿筛查和罕见病检测进行了优化[4] - 贝瑞基因计划将此项能力扩展到更多临床检测领域，如先天性肾上腺皮质增生症、脆性X染色体综合征、脊髓性肌萎缩症、杜氏肌营养不良症等复杂单基因疾病[6] - 此次批准推动了中国临床基因组学生态系统的进步，使实验室能够进行国内检测，与现有技术相比，有望缩短周转时间并提高诊断率[6]

Accessibility StatementSkip Navigation MINNEAPOLIS and TEL AVIV, Israel, Nov. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, and Nucleai, a leader in AI- powered multimodal spatial biology for precision medicine, today announced the presentation of pivotal data from the SECOMBIT clinical trial at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting.  Continue Reading Bio-Techne & Nucleai The study, c ...

Company Overview The AI Platform for Precision Medicine November 4, 2025 Cautionary notices This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking ...

– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 – – KOMET 017 Phase 3 trials to evaluate ziftomenib in combination with intensive and non-intensive chemotherapy in frontline AML are accelerating; ziftomenib being investigated in settings representing more than 50% of AML patients – – Two oral presentations at 2025 ASH Annual Meeting on ziftomenib in combination with venetoclax / azacitidine chemothera ...

Hims & Hers Health (NYSE:HIMS) Q3 2025 Earnings Call November 03, 2025 05:00 PM ET Speaker1Thank you for standing by. My name is Eric, and I will be your conference operator today. At this time, I would like to welcome everyone to the Hims & Hers Health third quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed b ...

Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Third quarter 2025 adjusted EBITDA was $10.3 million.E ...

Validation study data show AdvanceAD-Tx can identify patients with AD who have a ‘JAKi responder profile’ and a superior response to JAKi therapies compared to Th2-targeted therapiesFRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the launch of AdvanceAD-Tx™, a gene expression profile (GEP) test designed to guide systemic treatment decision making in patients ages 12 and ...

BioNTech (NasdaqGS:BNTX) Q3 2025 Earnings Call November 03, 2025 08:00 AM ET Company ParticipantsManoj Eradath - Senior Biotechnology Equity ResearcherUğur Şahin - CEODouglas Maffei - Vice President of Strategy and Investor RelationsRamón Zapata - CFOÖzlem Türeci - CMO and Co-FounderConference Call ParticipantsMalcolm Hoffman - AnalystYaron Werber - Senior Biotechnology AnalystDaina Graybosch - AnalystNone - AnalystTerence Flynn - Equity Research AnalystNic Jennings - AnalystMohit Bansal - AnalystJay Olson ...